Stockholm3 abstract wins 1st prize at European Academy of Urology

An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Academy of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69% compared to Standard of Care, while maintaining detection of significant cancer.

In total, 4,000 abstracts were presented at the annual European Academy of Urology, the largest scientific meeting in Europe within the field of Urology. The abstract “Risk-adapted screening with genomics and MRI: STHLM3 MR Phase 2 Trial” presented by Dr Tobias Nordström, Karolinska Institutet was awarded 1st Prize Best Abstract Oncology 2021.

The STHLM3 MR Trial is a randomized screen-by-invitation trial, comparing the standard test PSA with the Stockholm3 blood test when used with MRI-targeted or systematic biopsies for prostate cancer detection.

12,750 men in the age between 50 and 74 years participated in the trial. Compared to a screening strategy using PSA and systematic biopsies, Stockholm3 combined with MRI-targeted biopsies was associated with 69 percent fewer low-grade cancers and 53 percent fewer biopsy procedures.

“The results that Dr Nordström presented at EAU, in combination with our recently published paper in New England Journal of Medicine, provide evidence that the Stockholm3 test in combination with MRI provides a powerful and safe tool for prostate cancer screening. The significant reduction of overdetection and unnecessary procedures justifies introduction of general screening in men between the age of 50 and 74 to reduce their risk of dying of prostate cancer,” said Dr Henrik Grönberg, co-founder of A3P Biomedical and Professor of cancer epidemiology at Karolinska Institutet.

“These pivotal study results add to the significant body of data from studies of in total 80,000 men providing evidence of the value the Stockholm3 test. The healthcare providers in the Nordics that already transitioned to Stockholm3 are delivering outstanding results; 100 percent more aggressive cancers found, 50 percent reduction of unnecessary biopsies and 17 to 28 percent lower costs. A3P Biomedical is committed to making the Stockholm3 test available worldwide and look forward to work with our partners to improve men’s health and quality of life”, said David Rosen, CEO at A3P Biomedical.


Please enter your comment!
Please enter your name here